FindTrial
Sign In

Delgocitinib

DRUG9 trials

Sponsors

LEO Pharma, Icahn School of Medicine at Mount Sinai, Maryanne Makredes Senna

Conditions

Atopic DermatitisCentral Centrifugal Cicatricial AlopeciaChronic Hand EczemaFrontal Fibrosing AlopeciaLichen PlanopilarisLichen Sclerosus

Phase 1

Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children
CompletedNCT03826901
LEO PharmaAtopic Dermatitis
Start: 2019-02-20End: 2021-10-29Updated: 2025-02-24
Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema
CompletedNCT05486117
LEO PharmaChronic Hand Eczema
Start: 2022-09-06End: 2022-11-22Updated: 2025-04-04

Phase 2

Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris
RecruitingNCT07487948
Icahn School of Medicine at Mount SinaiCentral Centrifugal Cicatricial Alopecia, Lichen Planopilaris
Start: 2026-05-19End: 2027-12-31Target: 30Updated: 2026-07-10
Phase 2 Open Label Trial of Delgocitinib 20 mg/g Cream in Subjects With Frontal Fibrosing Alopecia (FFA)
Not yet recruitingNCT07671157
Maryanne Makredes SennaFrontal Fibrosing Alopecia
Start: 2026-09-10End: 2027-10-10Target: 30Updated: 2026-06-26

Phase 3

Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials
CompletedNCT04949841
LEO PharmaChronic Hand Eczema
Start: 2021-08-23End: 2023-09-18Updated: 2025-04-08
A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema
CompletedNCT05259722
LEO PharmaChronic Hand Eczema
Start: 2022-06-15End: 2023-12-05Updated: 2025-05-09
Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema
CompletedNCT05355818
LEO PharmaChronic Hand Eczema
Start: 2022-07-14End: 2024-12-17Updated: 2026-05-04
A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema
CompletedNCT06004050
LEO PharmaChronic Hand Eczema
Start: 2023-09-05End: 2025-09-12Updated: 2025-09-25
A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus
RecruitingNCT07335588
LEO PharmaLichen Sclerosus
Start: 2026-05-01End: 2028-12-29Target: 652Updated: 2026-06-09

Related Papers

Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial
Dermatology and Therapy2026-05-17
Editorial: Exploring innovative therapies for rare inflammatory skin diseases
Frontiers in Medicine2026-03-19
Systemic exposure and bioavailability of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema
Journal of the European Academy of Dermatology and Venereology2025-06-179 citations
Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial.
2025-04-169 citations
Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials.
2025-03-1110 citations
655 - Long-term safety and efficacy of delgocitinib cream for up to 36 weeks in adults with chronic hand eczema: results of the phase 3 open-label extension DELTA-3 trial
British Journal of Dermatology2024-08-015 citations